Yes, this combination can be taken together, but requires careful monitoring for specific drug interactions and side effects.
The combination of hydroxyzine, bupropion (Wellbutrin), and duloxetine is commonly used in clinical practice and can be safe, but requires attention to seizure risk, potential drug-drug interactions through CYP2D6 inhibition, and monitoring for CNS side effects.
Key Drug Interaction Concerns
CYP2D6 Inhibition - The Primary Issue
Both bupropion and duloxetine are moderate inhibitors of CYP2D6 12. When combined, this creates a cumulative inhibitory effect that can:
- Increase plasma levels of drugs metabolized by CYP2D6
- Potentially elevate hydroxybupropion levels (bupropion's active metabolite)
- Theoretically increase dopaminergic effects
One case report documented delirium in an elderly patient when bupropion was added to duloxetine, attributed to elevated hydroxybupropion levels causing excessive dopamine elevation 3. This resolved within 3 days of stopping bupropion.
Seizure Threshold Lowering
The FDA label explicitly warns that bupropion should be used with "extreme caution" when combined with other antidepressants that lower seizure threshold 11. Both duloxetine and bupropion can lower seizure threshold, requiring:
- Use of low initial doses with gradual titration
- Avoidance in patients with seizure history, eating disorders, or abrupt alcohol/benzodiazepine discontinuation
- Monitoring for factors that further lower threshold (sleep deprivation, stimulants, other medications)
Hydroxyzine Considerations
Hydroxyzine has minimal pharmacokinetic interactions with this combination. However:
- QT prolongation risk: Hydroxyzine can prolong QT interval 4, though this is dose-dependent and clinically significant primarily at higher doses
- Additive CNS effects: May cause increased sedation, though this can be therapeutically beneficial for anxiety/insomnia
- One animal study showed no additional benefit of combining duloxetine with hydroxyzine for anxiety 5, but this doesn't indicate safety concerns
Clinical Evidence for the Combination
Duloxetine + Bupropion Efficacy
Multiple studies support using duloxetine and bupropion together for treatment-resistant depression:
- A retrospective chart review of 10 patients showed significant improvement (CGI scores decreased from 4.4 to 2.1, p<0.0001) with 60% response rate and 30% remission rate 6
- Side effects were manageable: nausea, dry mouth, jitteriness/agitation, fatigue (each in 2 patients), with no life-threatening events
- A randomized controlled trial showed modest efficacy but noted higher atypical features predicted non-response 7
Practical Management Algorithm
Before Starting the Combination:
Screen for seizure risk factors:
- History of seizures, head trauma, CNS tumor
- Eating disorders (anorexia/bulimia)
- Abrupt benzodiazepine or alcohol discontinuation
- Medications that lower seizure threshold
Obtain baseline ECG if:
- Age >60 years
- Cardiac history
- Using hydroxyzine doses >50 mg/day
- Other QT-prolonging medications present
Check for CYP2D6 substrate medications:
- Type 1C antiarrhythmics (flecainide, propafenone) - narrow therapeutic index, high risk 4
- Beta-blockers (metoprolol)
- Other antipsychotics (haloperidol, risperidone, thioridazine)
Dosing Strategy:
- Start low, go slow with bupropion (begin 150 mg XL daily, not immediate release)
- Duloxetine: Standard dosing 30-60 mg daily
- Hydroxyzine: Keep ≤50 mg/day to minimize QT risk; use primarily as needed rather than standing doses
Monitoring Schedule:
Weeks 1-2:
- Weekly contact for suicidality screening (FDA black box warning for all antidepressants) 8
- Assess for agitation, restlessness, tremor, insomnia
Weeks 4-8:
- Evaluate therapeutic response
- Monitor for CNS toxicity: confusion, delirium (especially in elderly), excessive stimulation
- Check blood pressure (both drugs can increase BP)
Ongoing:
- If adding any new CYP2D6 substrates, consider dose reduction of the substrate medication
- Minimize alcohol use (bupropion warning) 1
Specific Populations Requiring Extra Caution
Elderly Patients:
- Higher delirium risk with the duloxetine-bupropion combination 3
- Start with lower doses (bupropion 100 mg SR, duloxetine 20-30 mg)
- More frequent monitoring for confusion, falls, orthostatic hypotension
Cardiac Patients:
- Avoid if on flecainide or other Type 1C antiarrhythmics without cardiology consultation 4
- Monitor ECG if using hydroxyzine regularly
- Both duloxetine and bupropion can increase blood pressure
When to Avoid This Combination
Absolute contraindications:
- Current seizure disorder or history of seizures
- Concurrent MAOI use (14-day washout required) 11
- Eating disorders (anorexia nervosa, bulimia)
- Abrupt benzodiazepine/alcohol discontinuation
Relative contraindications requiring specialist consultation:
- Congenital long QT syndrome
- Taking Type 1C antiarrhythmics
- Severe hepatic impairment
- Uncontrolled hypertension
Bottom Line
This three-drug combination is used successfully in clinical practice, particularly for treatment-resistant depression with comorbid anxiety. The main risks—seizures, CYP2D6 interactions, and CNS overstimulation—are manageable with appropriate patient selection, gradual dose titration, and systematic monitoring. Start with low doses of bupropion (150 mg XL), use standard duloxetine dosing, keep hydroxyzine as needed rather than standing, and monitor closely in the first 2-4 weeks 16.